bionanogenomics.com (BNGO) Price to Earnings Multiple

Bionano - graphic logo of issuer BNGO

Geopolitical instability and sanctions are severely hindering the global sales of DNA analysis systems and international scientific exchange. The market dynamics of Bionano Genomics, Inc. (BNGO) securities reflect a PE ratio of -0.50. Exclusive patents and US support serve as a business defense, although stringent FDA oversight complicates operations. Meanwhile, the company suffers from a liquidity shortage and high operating expenses.

Bionano Genomics (BNGO): Price to Earnings Ratio from 07/04/2022 to 11/16/2026

Analytical breakdowns for bionanogenomics.com (BNGO)

- market price and analyst price targets:
Summary company analysis:BNGO - Bionano Genomics
Original product of Bionano Genomics, Inc.

P/E measures the market value of a single unit of net profit, determining the payback period for investments. For Bionano Genomics, Inc. (BNGO), this calculation depends on operating margins during the assembly of complex genome mapping systems. The current P/E of the business is -0.50, reflecting market expectations regarding growth rates. The dynamics of this value help assess the risk of overpayment against the backdrop of logistics costs. It is critical for the investor to compare this ratio with the asset's liquidity.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Earnings Multiple|PACB - Price to Earnings Ratio|Benitec (BNTC) - Price to Earnings Ratio|DSGN: P/E Multiple|RCKT: Market Price to Net Income Ratio|FDMT (4D Molecular Therapeutics, Inc.) - P/E Multiple|lexeotx.com (LXEO) - Business Payback Period|P/E Multiple KRRO|Price to Earnings Ratio Editas Medicine, Inc. EDIT|Price to Earnings Ratio silence-therapeutics.com SLN|PRQR: Price to Earnings Multiple|CDXS - Price to Earnings Ratio|Business Payback Period Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Price to Earnings Ratio|Market Cap to Earnings Metagenomi, Inc. (MGX)|Price to Earnings Ratio DTIL|Price to Earnings Multiple GBIO (generationbio.com)|Price to Earnings Ratio Boundless Bio, Inc (BOLD)|P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Price to Earnings Ratio|PHIO: Price to Earnings Multiple|MBIO - Price to Earnings Ratio|Market Cap to Net Income RNAZ|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio